Interferon consensus

Blatt LM, Davis JM, Klein SB, Taylor MW (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 16 489 99... [Pg.231]

Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Lohr HF, Galle PR (2006) Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 26 319-325... [Pg.231]

Miglioresi L, Bacosi M, Russo E, Patrizi F, Saccenti P, Ursitti A, Angelis AD, Ricci GL (2003) Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res 27 253-259... [Pg.237]

Infergen (interferon alfacon-1 or consensus interferon) is an engineered interferon recently approved for the treatment of hepatitis C (Table 8.8). The development of infergen entailed initial sequence comparisons between a range of IFN-as. The product s amino acid sequence reflects the most frequently occurring amino acid residue in each corresponding position of these native interferons. A DNA sequence coding for the product was synthesized and inserted into E. coli. The recombinant product accumulates intracellularly as inclusion bodies. [Pg.228]

Infergen (interferon acon-1, or consensus interferon) is an engineered IFN recently approved for the treatment of hepatitis C (Table 4.8). The development of Infergen entailed initial... [Pg.211]

Consensus interferon (Con-IFN) Treatment of viral infections Rat Aerosol Tnax 25-30 min estimated bioavailability ca. 70% [101]... [Pg.211]

Niven, R.W., K.L. Whitcomb, M. Woodward, J. Liu, and C. Jornacion. 1995. Systemic absorption and activity of recombinant consensus interferons after intratracheal instillation and aerosol administration. Pharm. Res. 12 1889-1895. [Pg.240]

Interferon alfa is used as purified natural leukocyte or lymphoblastoid human interferon, or as a recombinant DNA preparation. Work to assign the most frequently observed amino acids at each position has led to a so-called consensus interferon alfa (1). Relatively low doses (3-10 MU three times a week) are now being used in most indications, except in AIDS-related Kaposi s sarcoma (up to 30 MU/day). Although the half-life is only 4-5 hours, its biological effects persist for 2-3 days. [Pg.1793]

Keeffe EB, Hollinger FB. Therapy of hepatitis C consensus interferon trials. Consensus Interferon Study Group. Hepatology 1997 26(3 Suppl l) S101-7. [Pg.1818]

Tong M J, Reddy K R, Lee W M, et al. (1997). Treatment of chronic hepatitis C with consensus interferon A multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatol. 26 747-754. [Pg.833]

The frequency of ophthalmological complications was determined in a retrospective analysis of 183 patients with hepatitis C virus infection, of whom 29 had diabetes and 85 had hypertension 71 received interferon alfa-2a, 100 received interferon alfa-2b, and 12 received consensus interferon... [Pg.774]

Hass HG, Klein R, Kaiser S. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NCSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1). J Clin Gastroenterol 2009 43(5) 470-6. [Pg.797]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...